FLT3 (Fms-like tyrosine kinase 3, CD135) is a protein that in humans is encoded by the FLT3 gene.The class III receptor tyrosine kinase family includes FLT3, a cytokine receptor. FLT3 is the cytokine Flt3 ligand (FLT3L)'sreceptor. On the surface of many hematopoietic progenitor cells, FLT-3 is expressed. The normal development of hemopoietic stem cells and progenitor cells depends on FLT3 signaling. One of the genes with the highest frequency of mutations in acute myeloid leukemia (AML) is FLT3.Furthermore, high FLT3 levels in blast cells from some AML patients without FLT3 mutations have been observed. The prognosis may be worse when these levels are high. Cell proliferation, differentiation, and survival are influenced by FLT3 signaling. FLT3 is crucial for the growth of lymphocytes (B and T cells), but not for the growth of other blood cells. The cytokines TNF-Alpha and TGF-Beta both inhibit FLT3 activity.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V77277 | AKN-028 acetate | AKN-028 acetate, a novel tyrosine kinase inhibitor (TKI), is a potent orally bioactive FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor (antagonist) with IC50 of 6 nM. | ||
V0587 | AMG 925 (FLX925; AMG925) | 1401033-86-0 | AMG 925 (also called FLX-925; AMG-925) is a novel, potent, selective and orally bioavailable FLT3/CDK4 dual inhibitor with potential antitumor activity. | |
V11821 | ATH686 | 853299-52-2 | ATH686 is a novel and selective FLT3 Inhibitor. | |
V33217 | BPR1J-097 | 1327167-19-0 | BPR1J-097 is a novel and potent FLT3 inhibitor (antagonist) with IC50 of 11 nM. | |
V77188 | BPR1J-097 Hydrochloride | BPR1J-097 HCl is a new and potent FLT3 inhibitor (antagonist) with IC50 of 11 nM. | ||
V0588 | Denfivontinib (G-749) | 1457983-28-6 | G-749 (G749) is a novel and potent FLT3 inhibitor with potential antineoplastic activity. | |
V69486 | Emavusertib hydrochloride (CA-4948 hydrochloride) | 2376399-42-5 | Emavusertib (CA-4948) HCl is a selective and orally bioactive IRAK4/FLT3 inhibitor. | |
V78480 | FLT3-IN-20 | FLT3-IN-20 (compound 34f) is a potent FLT3 inhibitor (antagonist) with IC50s of 1 and 4 nM for FLT3-D835Y and FLT3-ITD, respectively. | ||
V79168 | FLT3-IN-22 | FLT3-IN-22 (compound 22f) is a potent FLT3 inhibitor (antagonist) with IC50s of 0.941 nM and 0.199 nM for FLT3 and FLT3/D835Y, respectively. | ||
V79348 | FLT3-IN-23 | FLT3-IN-23 is an inhibitor (blocker/antagonist) of JFMS-like tyrosine kinase 3 (FLT3) with IC50 of 7.42 nM. | ||
V31516 | FLT3-IN-3 | 2229050-90-0 | FLT3-IN-3 is a potent FLT3 inhibitor, inhibiting FLT3 WT and FLT3 D835Y with IC50 of 13 and 8 nM, respectively. | |
V2632 | FLT3-IN-4 | 2304799-09-3 | FLT3-IN-4 is an orally bioavailable inhibitor of Fms-like tyrosine receptor kinase 3 (FLT3; IC50= 7 nM) for the study of acute myeloid leukemia. | |
V3135 | Gilteritinib hemifumarate | 1254053-84-3 | Gilteritinib hemifumarate (ASP2215; ASP-2215 hemifumarate; Xospata), the hemifumarate salt of Gilteritinib (ASP2215), is a marketed anti-AML drug acting as a dual inhibitor of FLT3/AXL with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL respectively. | |
V3134 | Gilteritinib(ASP2215) | 1254053-43-4 | Gilteritinib (formerly ASP-2215; ASP2215; Trade name: Xospata) is a potent small-molecule inhibitor of FLT3/AXL approved for treating acute myeloid leukemia (AML). | |
V78738 | HSK205 | HSK205 is a dual (bifunctional) inhibitor of FLT3 and haspin, with IC50 of 0.187 nM for FLT3. | ||
V78308 | LT-850-166 | LT-850-166 is a potent FLT3 inhibitor (antagonist) with the ability to overcome multiple FLT3 mutations. | ||
V2595 | Merestinib (LY2801653) | 1206799-15-6 | Merestinib (LY-2801653) is a novel, potent, orally bioavailable, type-II ATP competitive, slow-off small molecule inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. | |
V5202 | MRX-2843 (UNC2371) | 1429882-07-4 | MRX-2843 (also known as MRX2843; UNC-2371) is a novel, potent and orally bioactivesmall-molecule inhibitor of MERTK and FLT3 with anticancer activity. | |
V79535 | PLM-101 | PLM-101 is an orally bioavailable anticancer agent targeting FLT3 and RET with inhibitory effect against acute myeloid leukemia cells. | ||
V0584 | Quizartinib (AC220; AC010220) | 950769-58-1 | Quizartinib (formerly also know as AC-220; AC-010220,brand name Vanflyta in Japan) is a novel, potent, 2nd-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with potential anticancer activity. |